Ketan K Dhatariya1. 1. Elsie Bertram Diabetes Centre, Norfolk and Norwich University Hospitals NHS Foundation Trust, Colney Lane, Norwich, Norfolk NR4 7UY, UK; Norwich Medical School, University of East Anglia, Norwich, Norfolk NR4 7TJ, UK. Electronic address: ketan.dhatariya@nnuh.nhs.uk.
Abstract
AIMS: Diabetic ketoacidosis (DKA) remains one of the most frequently encountered diabetes related emergencies, and despite updates in management and increasing standardisation of care, still has an appreciable morbidity and mortality. This review focusses on the pathophysiology and epidemiology of DKA, but also on the importance of having a standardised definition. METHODS: Relevant data were reviewed where there was available basic science or clinical papers published in peer-reviewed international journals on DKA. These included consensus documents and national or international guidelines. RESULTS: The prevalence of DKA varies around the world, but part of this could be down to the way the condition is defined. Examples of this difference include the recent studies on sodium glucose co-transporter inhibitors in people with type 1 and type 2 diabetes which have all been associated with increased rates of DKA, but have highlighted how differences in definitions can make comparisons between agents very difficult. CONCLUSIONS: DKA should only be diagnosed when all three components are present - the 'D', the 'K' and the 'A'. In addition, the definitions used to diagnose DKA should be standardised - in particular for clinical trials.
AIMS: Diabetic ketoacidosis (DKA) remains one of the most frequently encountered diabetes related emergencies, and despite updates in management and increasing standardisation of care, still has an appreciable morbidity and mortality. This review focusses on the pathophysiology and epidemiology of DKA, but also on the importance of having a standardised definition. METHODS: Relevant data were reviewed where there was available basic science or clinical papers published in peer-reviewed international journals on DKA. These included consensus documents and national or international guidelines. RESULTS: The prevalence of DKA varies around the world, but part of this could be down to the way the condition is defined. Examples of this difference include the recent studies on sodiumglucose co-transporter inhibitors in people with type 1 and type 2 diabetes which have all been associated with increased rates of DKA, but have highlighted how differences in definitions can make comparisons between agents very difficult. CONCLUSIONS: DKA should only be diagnosed when all three components are present - the 'D', the 'K' and the 'A'. In addition, the definitions used to diagnose DKA should be standardised - in particular for clinical trials.
Authors: Marc Evans; Angharad R Morgan; Martin B Whyte; Wasim Hanif; Stephen C Bain; Philip A Kalra; Sarah Davies; Umesh Dashora; Zaheer Yousef; Dipesh C Patel; W David Strain Journal: Drugs Date: 2021-12-21 Impact factor: 9.546
Authors: Isabella Melena; Federica Piani; Kalie L Tommerdahl; Cameron Severn; Linh T Chung; Alexis MacDonald; Carissa Vinovskis; David Cherney; Laura Pyle; Carlos A Roncal-Jimenez; Miguel A Lanaspa; Arleta Rewers; Daniël H van Raalte; Gabriel Cara-Fuentes; Chirag R Parikh; Robert G Nelson; Meda E Pavkov; Kristen J Nadeau; Richard J Johnson; Petter Bjornstad Journal: J Diabetes Complications Date: 2022-04-28 Impact factor: 3.219
Authors: Eric S Kilpatrick; Alexandra E Butler; Linda Ostlundh; Stephen L Atkin; David B Sacks Journal: Diabetes Care Date: 2022-02-01 Impact factor: 19.112
Authors: Miguel Angel Casillas Santana; Juan Antonio Arreguín Cano; Alejandro Dib Kanán; Farid Alonso Dipp Velázquez; Paulina Del Carmen Sosa Munguía; Gabriel Alejandro Martínez Castañón; Brenda Eréndida Castillo Silva; Carolina Sámano Valencia; Marco Felipe Salas Orozco Journal: Medicina (Kaunas) Date: 2021-05-13 Impact factor: 2.430